Free Trial

Telix Pharmaceuticals (NASDAQ:TLX) Given Outperform Rating at William Blair

Telix Pharmaceuticals logo with Medical background

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report)'s stock had its "outperform" rating restated by investment analysts at William Blair in a report issued on Wednesday,RTT News reports.

A number of other equities analysts have also weighed in on the company. HC Wainwright began coverage on Telix Pharmaceuticals in a research note on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price objective for the company. Wedbush reaffirmed an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Thursday, June 12th.

View Our Latest Stock Analysis on Telix Pharmaceuticals

Telix Pharmaceuticals Price Performance

NASDAQ:TLX traded up $1.23 during mid-day trading on Wednesday, hitting $16.92. 105,223 shares of the company traded hands, compared to its average volume of 29,148. The stock's fifty day moving average price is $16.78 and its 200-day moving average price is $16.95. Telix Pharmaceuticals has a one year low of $13.61 and a one year high of $30.36. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78.

Hedge Funds Weigh In On Telix Pharmaceuticals

An institutional investor recently bought a new position in Telix Pharmaceuticals stock. Private Advisor Group LLC purchased a new position in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 10,140 shares of the company's stock, valued at approximately $170,000.

Telix Pharmaceuticals Company Profile

(Get Free Report)

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

Featured Articles

Should You Invest $1,000 in Telix Pharmaceuticals Right Now?

Before you consider Telix Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.

While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines